Biotechnological Applications in Medicine — Core Principles
Core Principles
Biotechnological applications in medicine harness genetic engineering and molecular biology to revolutionize healthcare. Key areas include the production of therapeutic proteins like recombinant human insulin, which is safer and more abundant than animal-derived versions, and recombinant vaccines for enhanced safety and efficacy.
Gene therapy offers a promising avenue for correcting genetic defects, exemplified by the treatment of ADA deficiency by introducing a functional gene. Molecular diagnostics, utilizing techniques such as PCR and ELISA, enable early and accurate detection of diseases by identifying pathogen DNA/RNA or specific antigens/antibodies.
Furthermore, transgenic animals serve as 'bioreactors' for producing valuable pharmaceuticals and as 'disease models' for studying human conditions and testing new drugs. These applications collectively aim to provide more targeted, effective, and safer medical solutions, transforming disease management and prevention.
Often confused with
Side-by-side differences the NEET paper likes to test.
| Aspect | Biotechnological Applications in Medicine | Traditional Insulin Production vs. Recombinant Human Insulin Production |
|---|---|---|
| Source | Pancreas of slaughtered animals (pigs, cattle) | Genetically engineered bacteria (*E. coli*) or yeast |
| Molecular Structure | Slightly different from human insulin (e.g., single amino acid difference in pig insulin) | Identical to natural human insulin |
| Immunogenicity/Allergic Reactions | Higher risk of allergic reactions and immune responses in some patients | Very low risk of allergic reactions due to human-identical structure |
| Supply | Limited supply, dependent on animal availability | Virtually unlimited and consistent supply due to large-scale microbial fermentation |
| Purity and Safety | Potential for contamination with animal proteins or pathogens | High purity, free from animal contaminants and pathogens |
| Cost (Initial) | Initially cheaper, but variable due to animal sourcing | Higher initial development cost, but mass production can lower per-unit cost |
The shift from traditional animal-derived insulin to recombinant human insulin represents a significant advancement in medical biotechnology. Recombinant insulin offers superior safety due to its identical human structure, eliminating allergic reactions and potential pathogen transmission.
It also ensures a stable and abundant supply, overcoming the limitations and ethical concerns associated with animal sourcing. This comparison highlights the benefits of genetic engineering in producing safer and more effective biopharmaceuticals.
Why it is tested: For NEET, understanding this difference is crucial as it exemplifies the core advantages of biotechnological products over traditional ones, particularly in terms of safety, efficacy, and scalability. Questions often focus on the reasons for this transition and the specific benefits of recombinant technology.